Mydecine Innovations Group (OTCPK:MYCO.F) - Aktienkurs, Nachrichten und Analyse

MYCO.F Aktienübersicht

MYCO.F grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	0/6
Dividenden	0/6

Belohnungen

Die Erträge sind in den letzten 5 Jahren um 8.7% pro Jahr gestiegen.

Risikoanalyse

Hat weniger als 1 Jahr Cash Runway

Hat keine nennenswerte Marktkapitalisierung ($333K)

Negatives Eigenkapital

Erzielt weniger als 1 Million USD an Einnahmen (CA$0)

+ 2 mehr Risiken

Mydecine Innovations Group Inc. Wettbewerber

Kid Castle Educational

OTCPK:KDCE

US$357.2k

TFF Pharmaceuticals

NasdaqCM:TFFP

US$1.4m

SciSparc

NasdaqCM:SPRC

US$790.0k

AmeriCann

OTCPK:ACAN

US$465.9k

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Mydecine Innovations Group
Historische Aktienkurse
Aktueller Aktienkurs	US$0.0054
52-Wochen-Hoch	US$0.095
52-Wochen-Tief	US$0.0001
Beta	2.77
11 Monat Veränderung	42.11%
3 Monate Veränderung	-27.03%
1 Jahr Veränderung	-93.72%
33 Jahre Veränderung	-99.93%
5 Jahre Veränderung	-99.95%
Veränderung seit IPO	-100.00%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	MYCO.F	US Pharmaceuticals	US Markt
7D	-21.7%	2.6%	0.5%
1Y	-93.7%	13.1%	30.7%

Rendite im Vergleich zur Industrie: MYCO.F unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 13.1% erzielte.

Rendite vs. Markt: MYCO.F hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 30.7 erzielte.

Preisvolatilität

Is MYCO.F's price volatile compared to industry and market?
MYCO.F volatility
MYCO.F Average Weekly Movement	104.7%
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stabiler Aktienkurs: MYCO.FDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: MYCO.FDie wöchentliche Volatilität der Aktie ist im letzten Jahr von 2907% auf 105% gesunken, liegt aber immer noch höher als bei 75% der Aktien von US.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2013	3	Josh Bartch	www.mydecine.com

Mydecine Innovations Group Inc. ist ein Biotechnologieunternehmen, das sich mit der Erforschung, Entwicklung und Vermarktung von Psilocybin-Produkten zur Behandlung psychischer Erkrankungen befasst. Das Unternehmen konzentriert sich in erster Linie auf die Behandlung von Nikotinsucht und posttraumatischer Belastungsstörung. Zu seinen führenden Produktkandidaten gehört MYCO-005.

Mydecine Innovations Group Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Mydecine Innovations Group im Vergleich zum Marktanteil des Unternehmens?
MYCO.F grundlegende Statistiken
Marktanteil	US$333.48k
Gewinn(TTM)	-US$8.89m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

0.0x

Kurs-Gewinn-Verhältnis

Ist MYCO.F zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
MYCO.F Gewinn- und Verlustrechnung (TTM)
Einnahmen	CA$0
Kosten der Einnahmen	CA$0
Bruttogewinn	CA$0
Sonstige Ausgaben	CA$12.46m
Umsatz	-CA$12.46m

Zuletzt gemeldete Gewinne

Sep 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.20
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	-37.4%

Wie hat sich MYCO.F auf lange Sicht entwickelt?

Historische Performance und Vergleiche

MYCO.F Aktienübersicht

Belohnungen

Risikoanalyse

Mydecine Innovations Group Inc. Wettbewerber

OTCPK:KDCE

US$357.2k

NasdaqCM:TFFP

US$1.4m

NasdaqCM:SPRC

US$790.0k

OTCPK:ACAN

US$465.9k

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Recent updates

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Mydecine Innovations Group Inc., Annual General Meeting, Apr 20, 2023

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Pangenomic Health Inc. (CNSX:NARA) completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F).

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 4.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. Announces Appointment of John Ross as Its Chief Financial Officer

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering.

Pangenomic Health Inc. (CNSX:NARA) signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million.

Mydecine Innovations Group Inc. Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces CFO Changes

Mydecine Innovations Group Inc. Announces Resignation of Directors

Mydecine Files Full Patent Application Covering Myco-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Mydecine Innovations Group Inc. Announces Board Changes

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 4 million.

Mydecine Innovations Group Inc. has completed a Composite Units Offering.

Mydecine Innovations Group Inc., Annual General Meeting, May 26, 2022

Mydecine Innovations Group Inc. Reports Positive Pre-IND Meeting with FDA for MYCO-001 Smoking Cessation Study

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Innovations Group Inc. to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic- Assisted Psychotherapy for Patients

Mydecine Innovations Group Inc. Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

Mydecine Innovations Group Inc. Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Innovations Group Inc. announced that it expects to receive CAD 5.5 million in funding

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Mydecine Innovations Group Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Mydecine Provides Business Update

Mydecine Innovations Group Expands Portfolio of Novel Molecules Filing New Patent for MDMA-Like Compounds

Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

Mydecine Unveils Artificial Intelligence Drug Discovery Program

Mydecine Innovations Group Discovers over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms

Health Canada Approves Expansion of Mydecine's Cultivation Capabilities for Psilocybin Producing Mushrooms

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms

Mydecine Innovations Group Announces Management Changes

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies Its Clinical and Commercial Supply Chain

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 15 million.

Mydecine Innovations Group Announces Management Changes

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors

Mydecine Innovations Group Announces the Filing of Seven Provisional Patent Applications with the United States Patent and Trademark Office

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

Mydecine Innovations Group Launches Mindleap app

Mydecine Innovations Group Inc. Announces Appointment of Rakesh Jetly as Chief Medical Officer

Mydecine Innovations Group Inc. (CNSX:MYCO) completed the acquisition of NeuroPharm Inc.

NewLeaf Brands Inc. (CNSX:NLB) completed the acquisition of Mindleap Health.

Mydecine Innovations Group Inc. announced that it has received CAD 2.4 million in funding

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Mydecine Innovations Group Inc.'s Grundlagenzusammenfassung

0.0x

Erträge & Einnahmen